Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Arcutis Biotherapeutics, Inc. (ARQT) vs Legend Biotech Corporation Sponsored ADR (LEGN)

Arcutis Biotherapeutics, Inc. and Legend Biotech Corporation Sponsored ADR are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Legend Biotech Corporation Sponsored ADR are of similar size ($3.7B and $3.4B). Legend Biotech Corporation Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 122×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against 59.6%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −7.20%) and the higher return on invested capital (23.6% vs −9.54%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 11 and Legend Biotech Corporation Sponsored ADR on 6.

Valuation

Metric ARQT LEGN Biotechnology median
P/E 122.36 n/m 7.88
P/S 7.57 2.81 11.47
P/B 15.93 2.91 2.52
Price to free cash flow 145.96 n/m 21.16
EV/EBITDA 95.16 n/m 0.74
EV/Sales 7.29 2.31 10.73
Earnings yield 0.82% (2.59%) (28.84%)
Free cash flow yield 0.69% (3.42%) (23.03%)

Profitability

Metric ARQT LEGN Biotechnology median
Gross margin 91.14% 56.58% 65.16%
Operating margin 7.38% (5.06%) 0.00%
Net margin 6.15% (7.20%) 0.00%
Free cash flow margin 8.42% (9.58%) 0.00%
Return on equity 15.86% (8.08%) (57.72%)
Return on assets 6.78% (5.32%) (49.22%)
Return on invested capital 23.62% (9.54%) 0.00%

Growth

Metric ARQT LEGN Biotechnology median
Revenue growth (TTM) 76.11% 59.55% 5.64%
EPS growth (last fiscal year) 88.79% (66.34%) —
Revenue growth, 5-year CAGR — 65.93% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARQT LEGN Biotechnology median
Debt to equity 0.49 0.13 0.00
Current ratio 2.92 3.04 4.73
Net debt to EBITDA 11.64 2.31 0.96

Dividend

Metric ARQT LEGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARQT LEGN Biotechnology median
Market cap 3.39b 3.69b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack